Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

497 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[The importance of pathology in the German prostate cancer study PREFERE].
Kristiansen G, Stöckle M, Albers P, Schmidberger H, Martus P, Wellek S, Härter M, Bussar-Maatz R, Wiegel T. Kristiansen G, et al. Among authors: stockle m. Pathologe. 2013 Sep;34(5):449-62. doi: 10.1007/s00292-013-1788-8. Pathologe. 2013. PMID: 23963533 Review. German.
[PREFERE - Study on the rise].
Ohlmann CH, Stöckle M, Albers P, Schmidberger H, Härter M, Kristiansen G, Martus P, Wellek S, Bussar-Maatz R, Wiegel T. Ohlmann CH, et al. Among authors: stockle m. Urologe A. 2016 Mar;55(3):313-7. doi: 10.1007/s00120-016-0047-z. Urologe A. 2016. PMID: 26908120 Clinical Trial. German.
Termination rates and histological reclassification of active surveillance patients with low- and early intermediate-risk prostate cancer: results of the PREFERE trial.
Albers P, Wiegel T, Schmidberger H, Bussar-Maatz R, Härter M, Kristiansen G, Martus P, Meisner C, Wellek S, Grozinger K, Renner P, Burmester M, Schneider F, Stöckle M. Albers P, et al. Among authors: stockle m. World J Urol. 2021 Jan;39(1):65-72. doi: 10.1007/s00345-020-03154-7. Epub 2020 Mar 18. World J Urol. 2021. PMID: 32189088 Free PMC article. Clinical Trial.
Results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial).
Wiegel T, Albers P, Bartkowiak D, Bussar-Maatz R, Härter M, Kristiansen G, Martus P, Wellek S, Schmidberger H, Grozinger K, Renner P, Schneider F, Burmester M, Stöckle M. Wiegel T, et al. Among authors: stockle m. J Cancer Res Clin Oncol. 2021 Jan;147(1):235-242. doi: 10.1007/s00432-020-03327-2. Epub 2020 Sep 4. J Cancer Res Clin Oncol. 2021. PMID: 32886212 Free PMC article. Clinical Trial.
[Localised prostate cancer: the PREFERE trial].
Stöckle M, Bussar-Maatz R. Stöckle M, et al. Z Evid Fortbild Qual Gesundhwes. 2012;106(5):333-5; discussion 335. doi: 10.1016/j.zefq.2012.05.004. Epub 2012 Jun 18. Z Evid Fortbild Qual Gesundhwes. 2012. PMID: 22818151 Clinical Trial. German.
Reply to Andreas Boehle, Frank Kahmann, Thomas Oliver Henkel, Joerg Zimmermann and Stefan Machten's to the Letter to the editor Re: results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial).
Wiegel T, Albers P, Bartkowiak D, Bussar-Maatz R, Härter M, Kristiansen G, Martus P, Wellek S, Schmidberger H, Grozinger K, Renner P, Schneider F, Burmester M, Stöckle M. Wiegel T, et al. Among authors: stockle m. J Cancer Res Clin Oncol. 2021 Apr;147(4):1273-1274. doi: 10.1007/s00432-021-03549-y. J Cancer Res Clin Oncol. 2021. PMID: 33625578 Free PMC article. No abstract available.
Correction to: Results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial).
Wiegel T, Albers P, Bartkowiak D, Bussar-Maatz R, Härter M, Kristiansen G, Martus P, Wellek S, Schmidberger H, Grozinger K, Renner P, Schneider F, Burmester M, Stöckle M. Wiegel T, et al. Among authors: stockle m. J Cancer Res Clin Oncol. 2021 Jan;147(1):243-244. doi: 10.1007/s00432-020-03497-z. J Cancer Res Clin Oncol. 2021. PMID: 33346877 Free PMC article. No abstract available.
497 results